Valeant Pharma Reports Approval Of Jublia® For The Treatment Of Onychomycosis In Canada
October 03, 2013 at 08:04 AM EDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) announced today that its wholly owned subsidiary, Valeant Canada LP, has received notice that the New Drug Submission for Jublia® has been approved from the Canadian regulatory authority, Health Canada. Jublia® (efinaconazole 10% topical solution) is indicated for the treatment of mild
